Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 tumor uptake study of BI 765063 and BI 770371 with ezabenlimab in advanced solid tumors
NL-OMON59624Phase 1Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of BI 765063, BI 770371 and ezabenlimab in head and neck squamous cell carcinoma (HNSCC), melanoma and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Primary endpoint(s). Started Nov 2021; status: active, not recruiting.
02
Drugs
BI 765063BI 770371ezabenlimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)melanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59624.